Selected article for: "blood pressure and clinical hypertension"
Author: Maximilian F Konig; Mike Powell; Verena Staedtke; Ren-Yuan Bai; David L Thomas; Nicole Fischer; Sakibul Huq; Adham M Khalafallah; Allison Koenecke; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Joshua T Vogelstein; Susan Athey; Shibin Zhou; Chetan Bettegowda
Title: Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
  • Document date: 2020_4_8
    • ID: 0lwmzjxz_12
    Snippet: Taken together, these results extend preclinical findings to support a clinical rationale for studying ⍺1-AR antagonists in the prophylaxis of severe COVID-19 and states of local and systemic immune dysregulation. Prazosin is inexpensive and safe, as has been documented by long-term treatment of millions of patients with benign prostatic hyperplasia, hypertension, and other conditions. However, all drugs can have unanticipated side effects in d.....
    Document: Taken together, these results extend preclinical findings to support a clinical rationale for studying ⍺1-AR antagonists in the prophylaxis of severe COVID-19 and states of local and systemic immune dysregulation. Prazosin is inexpensive and safe, as has been documented by long-term treatment of millions of patients with benign prostatic hyperplasia, hypertension, and other conditions. However, all drugs can have unanticipated side effects in different clinical contexts, and the incompletely understood relationship between hypertension and COVID-19 suggests caution in using any agent that impacts blood pressure(14).

    Search related documents:
    Co phrase search for related documents
    • benign prostatic hyperplasia and long term: 1, 2, 3, 4, 5
    • benign prostatic hyperplasia and prostatic hyperplasia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53
    • blood impact and clinical rationale: 1
    • blood impact and immune dysregulation: 1
    • blood impact and long term: 1, 2, 3, 4, 5, 6, 7
    • blood impact and long term treatment: 1
    • clinical contexts and different clinical contexts: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • clinical contexts and long term: 1, 2
    • clinical rationale and immune dysregulation: 1, 2
    • clinical rationale and long term: 1, 2, 3, 4, 5, 6
    • condition hypertension and long term: 1, 2, 3